Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 021252
Company: ABBVIE
Company: ABBVIE
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
CANASA | MESALAMINE | 500MG | SUPPOSITORY;RECTAL | Discontinued | None | No | No |
CANASA | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | AB | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
01/05/2001 | ORIG-1 | Approval | Type 5 - New Formulation or New Manufacturer | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21252lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/21252ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-252_Canasa.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
10/24/2023 | SUPPL-30 | Labeling-Package Insert, Labeling-Medication Guide |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021252Orig1s030ltr.pdf | |
11/16/2022 | SUPPL-29 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021252s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021252Orig1s029ltr.pdf | |
11/01/2021 | SUPPL-28 | Labeling-Package Insert, Labeling-Medication Guide |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021252Orig1s028ltr.pdf | |
10/01/2020 | SUPPL-25 | Labeling-Medication Guide, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021252Orig1s025ltr.pdf | |
07/27/2017 | SUPPL-23 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021252s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021252Orig1s023ltr.pdf | |
07/30/2014 | SUPPL-21 | Manufacturing (CMC) |
Label is not available on this site. |
||
12/17/2013 | SUPPL-20 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021252Orig1s020ltr.pdf | |
01/02/2014 | SUPPL-19 | Manufacturing (CMC) |
Label is not available on this site. |
||
12/24/2013 | SUPPL-18 | Manufacturing (CMC) |
Label is not available on this site. |
||
05/03/2013 | SUPPL-16 | Manufacturing (CMC) |
Label is not available on this site. |
||
09/02/2016 | SUPPL-14 | Efficacy-New Patient Population |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021252s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021252Orig1s014ltr.pdf | |
02/06/2013 | SUPPL-13 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021252Orig1s013ltr.pdf | |
05/23/2008 | SUPPL-9 | Labeling-Container/Carton Labels, Labeling-Package Insert |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021252s009ltr.pdf |
06/08/2006 | SUPPL-7 | Labeling |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021252s007LTR.pdf |
09/23/2004 | SUPPL-6 | Labeling |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21252s006ltr.pdf |
11/05/2004 | SUPPL-5 | Efficacy-New Dosing Regimen |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21252s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21252s005ltr.pdf | |
10/14/2003 | SUPPL-2 | Labeling |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21252slr002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
10/24/2023 | SUPPL-30 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf | |
10/24/2023 | SUPPL-30 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf | |
11/16/2022 | SUPPL-29 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021252s029lbl.pdf | |
11/01/2021 | SUPPL-28 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf | |
11/01/2021 | SUPPL-28 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf | |
10/01/2020 | SUPPL-25 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf | |
10/01/2020 | SUPPL-25 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf | |
07/27/2017 | SUPPL-23 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021252s023lbl.pdf | |
09/02/2016 | SUPPL-14 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021252s014lbl.pdf | |
12/17/2013 | SUPPL-20 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s020lbl.pdf | |
02/06/2013 | SUPPL-13 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s013lbl.pdf | |
11/05/2004 | SUPPL-5 | Efficacy-New Dosing Regimen | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21252s005lbl.pdf | |
01/05/2001 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21252lbl.pdf |
CANASA
SUPPOSITORY;RECTAL; 1GM
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
CANASA | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | Yes | AB | 021252 | ABBVIE |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 205654 | ACTAVIS MID ATLANTIC |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 208362 | AMRING PHARMS |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 213377 | ANNORA PHARMA |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 204354 | MYLAN |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 207448 | PHARM SOURCING |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 202065 | SANDOZ |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 208953 | ZYDUS PHARMS |